company background image
CARA logo

Cara Therapeutics NasdaqGM:CARA Stock Report

Last Price

US$0.95

Market Cap

US$46.3m

7D

4.7%

1Y

-90.8%

Updated

01 Mar, 2024

Data

Company Financials +

Cara Therapeutics, Inc.

NasdaqGM:CARA Stock Report

Market Cap: US$46.3m

CARA Stock Overview

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States.

CARA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Cara Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cara Therapeutics
Historical stock prices
Current Share PriceUS$0.95
52 Week HighUS$10.39
52 Week LowUS$0.50
Beta0.59
1 Month Change67.96%
3 Month Change-10.38%
1 Year Change-90.76%
3 Year Change-94.75%
5 Year Change-94.28%
Change since IPO-92.64%

Recent News & Updates

We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Feb 16
We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Recent updates

We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Feb 16
We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%

Dec 19
The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%

News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts

Nov 04
News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts

Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Oct 25
Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Jul 20
Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper

Jun 04
Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper

News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat

Mar 11
News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat

Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates

Feb 15
Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates

We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth

Feb 06
We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth

We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow

Oct 18
We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow

Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients

Sep 28

Cara Therapeutics hires new finance chief

Sep 12

Cara Therapeutics: All Eyes On Korsuva Launch Metrics

Sep 01

Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients

Aug 19

Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M

Aug 08

Calls A Much Safer Way To Buy Cara Therapeutics

Jun 24

We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Jun 15
We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts

May 12
Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts

Taking A (Speculative) Position In Cara Therapeutics

Mar 21

Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth

Mar 09
Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth

Cara Therapeutics: De-Risked And Extremely Attractive

Dec 25

Checking Back In On Cara Therapeutics

Nov 01

Cara And IV Korsuva: Key Bull And Bear Investor Thoughts Going Into Upcoming PDUFA

Aug 21

The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically

Aug 15
The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically

Cara Therapeutics: 200% Upside Possible With FDA Approval

Aug 11

Cara Therapeutics: PDUFA Ahead Makes Current Drop Attractive

Jul 19

It's Unlikely That The CEO Of Cara Therapeutics, Inc. (NASDAQ:CARA) Will See A Huge Pay Rise This Year

May 28
It's Unlikely That The CEO Of Cara Therapeutics, Inc. (NASDAQ:CARA) Will See A Huge Pay Rise This Year

Shareholder Returns

CARAUS PharmaceuticalsUS Market
7D4.7%-1.4%0.4%
1Y-90.8%24.2%24.9%

Return vs Industry: CARA underperformed the US Pharmaceuticals industry which returned 24.2% over the past year.

Return vs Market: CARA underperformed the US Market which returned 24.9% over the past year.

Price Volatility

Is CARA's price volatile compared to industry and market?
CARA volatility
CARA Average Weekly Movement20.7%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: CARA's share price has been volatile over the past 3 months.

Volatility Over Time: CARA's weekly volatility has increased from 15% to 21% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004106Chris Posnerhttps://www.caratherapeutics.com

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica.

Cara Therapeutics, Inc. Fundamentals Summary

How do Cara Therapeutics's earnings and revenue compare to its market cap?
CARA fundamental statistics
Market capUS$46.32m
Earnings (TTM)-US$116.51m
Revenue (TTM)US$21.23m

2.4x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CARA income statement (TTM)
RevenueUS$21.23m
Cost of RevenueUS$112.66m
Gross Profit-US$91.44m
Other ExpensesUS$25.08m
Earnings-US$116.51m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Mar 04, 2024

Earnings per share (EPS)-2.14
Gross Margin-430.81%
Net Profit Margin-548.95%
Debt/Equity Ratio0%

How did CARA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.